NYSE:PFE - Pfizer Stock Price, Price Target & More

$36.63 +0.10 (+0.27 %)

(As of 04/22/2018 06:33 AM ET)

Previous Close$36.63

Today's Range$36.47 - $36.79

52-Week Range$31.67 - $39.43

Volume21.23 million shs

Average Volume19.73 million shs

Market Capitalization$218.05 billion

P/E Ratio13.82

Dividend Yield3.71%

Beta0.9

About Pfizer (NYSE:PFE)

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:PFE

CUSIP71708110

Webwww.pfizer.com

Phone212-733-2323

Debt

Debt-to-Equity Ratio0.47%

Current Ratio1.35%

Quick Ratio1.10%

Price-To-Earnings

Trailing P/E Ratio13.82

Forward P/E Ratio12.38

P/E Growth1.83

Sales & Book Value

Annual Sales$52.55 billion

Price / Sales4.15

Cash Flow$3.7492 per share

Price / Cash9.77

Book Value$12.02 per share

Price / Book3.05

Profitability

EPS (Most Recent Fiscal Year)$2.65

Net Income$21.31 billion

Net Margins40.55%

Return on Equity25.21%

Return on Assets9.42%

Miscellaneous

Employees90,200

Outstanding Shares5,952,870,000

How to Become a New Pot Stock Millionaire

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Monday, December 18th. Shareholders of record on Friday, February 2nd will be given a dividend of $0.34 per share on Thursday, March 1st. This represents a $1.36 annualized dividend and a yield of 3.71%. The ex-dividend date is Thursday, February 1st. This is a boost from Pfizer's previous quarterly dividend of $0.32. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer announced that its Board of Directors has authorized a share repurchase plan on Tuesday, December 19th 2017, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's management believes its stock is undervalued.

How were Pfizer's earnings last quarter?

Pfizer (NYSE:PFE) announced its quarterly earnings results on Tuesday, January, 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.56 by $0.06. The biopharmaceutical company earned $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. Pfizer's quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.47 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer updated its FY18 earnings guidance on Tuesday, January, 30th. The company provided earnings per share guidance of $2.90-3.00 for the period, compared to the Thomson Reuters consensus estimate of $2.78. The company issued revenue guidance of $53.5-55.5 billion, compared to the consensus revenue estimate of $53.82 billion.

What price target have analysts set for PFE?

19 analysts have issued 1-year price targets for Pfizer's shares. Their forecasts range from $31.00 to $43.00. On average, they expect Pfizer's share price to reach $39.2222 in the next year. View Analyst Ratings for Pfizer.

What are Wall Street analysts saying about Pfizer stock?

Here are some recent quotes from research analysts about Pfizer stock:

1. According to Zacks Investment Research, "Pfizer faces headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition, which are hurting the top line. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost cuts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio offers a strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. Additionally, Pfizer’s shares have outperformed the industry this year so far. Pfizer has a positive record of earnings surprises in recent quarters. Estimates have gone up slightly ahead of its Q1 earnings release." (4/12/2018)
2. BMO Capital Markets analysts commented, "We are highly confident the deal will close as the purchase agreement removes IP risk and development risks, and creates significant shareholder value. We believe there is minimal risk for the deal being blocked due to anti-trust considerations CTP-543 Phase IIa initiated with top-line results expected 1Q18. The phase IIa trial will enroll approximately 100 patients spread across 4 active arms of differing doses (4, 8, 12 and 16 mg BID) and a placebo comparator. The primary endpoint for the trial will be measured using the severity of alopecia tool (SALT) after patients undergo 24 weeks of dosing. An additional 28 weeks of dosing of CTP-543 is planned for all patients enrolled in the study. If successfully developed, we anticipate a significant pricing discount for CTP-543 relative to Jakafi – owned by Incyte (INCY, Non-Rated). The earlier delay to initiate the trial due to clinical supply delays, which lasted around 2 months, has been resolved." (4/27/2017)

Are investors shorting Pfizer?

Pfizer saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 98,318,686 shares, a decrease of 31.2% from the March 15th total of 142,877,234 shares. Based on an average daily volume of 23,708,988 shares, the days-to-cover ratio is presently 4.1 days. Approximately 1.7% of the company's shares are sold short.

Who are some of Pfizer's key competitors?

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Sanofi (SNY), Bayer (BAYRY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX) and Takeda Pharmaceutical (TKPYY).

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:

Mr. Ian C. Read, Chairman & CEO (Age 64)
Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Has Pfizer been receiving favorable news coverage?

Media coverage about PFE stock has trended positive recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pfizer earned a media sentiment score of 0.44 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.71 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $36.63.

How big of a company is Pfizer?

Pfizer has a market capitalization of $218.05 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

MarketBeat Community Rating for Pfizer (PFE)

Community Ranking:		3.3 out of 5 ( )
Outperform Votes:		960 (Vote Outperform)
Underperform Votes:		513 (Vote Underperform)
Total Votes:		1,473

MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Pfizer (NYSE:PFE) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Pfizer in the last 12 months. Their average twelve-month price target is $39.2222, suggesting that the stock has a possible upside of 7.08%. The high price target for PFE is $43.00 and the low price target for PFE is $31.00. There are currently 1 sell rating, 10 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Buy
Consensus Rating Score:	2.37	2.42	2.53	2.53
Ratings Breakdown:	1 Sell Rating(s) 10 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 9 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 6 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$39.2222	$39.3889	$37.9333	$38.3125
Price Target Upside:	7.08% upside	9.75% upside	3.81% upside	6.93% upside

Pfizer (NYSE:PFE) Consensus Price Target History

Price Target History for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/13/2018	Jefferies Group	Set Price Target	Hold	$38.00	Low
4/12/2018	Citigroup	Reiterated Rating	Sell		Medium
4/11/2018	Berenberg Bank	Reiterated Rating	Neutral	$37.00	Low
4/5/2018	Barclays	Downgrade	Overweight -> Equal Weight	$41.00 -> $38.00	Medium
4/2/2018	BMO Capital Markets	Set Price Target	Buy	$43.00	Medium
1/31/2018	Credit Suisse Group	Boost Price Target	Neutral -> Neutral	$37.00 -> $39.00	Medium
1/31/2018	Leerink Swann	Boost Price Target	Market Perform -> Market Perform	$35.00 -> $38.00	Medium
1/31/2018	UBS	Set Price Target	Buy	$42.00	Medium
1/31/2018	Morgan Stanley	Boost Price Target	Overweight -> Buy	$41.00 -> $43.00	Medium
1/31/2018	Societe Generale	Set Price Target	Neutral	$40.00	Medium
1/30/2018	Goldman Sachs	Set Price Target	Neutral	$36.00	High
1/30/2018	Morningstar	Set Price Target	Neutral	$38.00	High
1/30/2018	Bank of America	Set Price Target	Buy	$40.00	Medium
1/30/2018	JPMorgan Chase	Reiterated Rating	Buy		Low
1/30/2018	Sanford C. Bernstein	Set Price Target	Buy	$43.00	Low
1/29/2018	SunTrust Banks	Reiterated Rating	Hold -> Hold	$33.00 -> $40.00	Low
1/2/2018	Nord/LB	Reiterated Rating	Neutral		Low
12/6/2017	Deutsche Bank	Set Price Target	Buy	$38.00	Low
8/14/2017	Cowen	Set Price Target	Buy	$43.00	Low
2/1/2017	Atlantic Securities	Set Price Target	Buy	$37.00	N/A
1/21/2017	Piper Jaffray	Set Price Target	Buy	$53.00	N/A
12/2/2016	Guggenheim	Initiated Coverage	Neutral		N/A
11/2/2016	Argus	Downgrade	Buy -> Hold		N/A
5/4/2016	Independent Research	Set Price Target	Neutral	$37.00	N/A

(Data available from 4/22/2016 forward)

Pfizer (NYSE:PFE) Earnings History and Estimates Chart

Earnings by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Earnings Estimates

2018 EPS Consensus Estimate: $2.96

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.67	$0.75	$0.72
Q2 2018	2	$0.70	$0.75	$0.73
Q3 2018	2	$0.75	$0.78	$0.77
Q4 2018	2	$0.69	$0.82	$0.76

Pfizer (NYSE PFE) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/1/2018		$0.70					N/A
1/30/2018	Q4 2017	$0.5620	$0.62	$13.6746 billion	$13.7030 billion	View	Listen
10/31/2017	Q3 2017	$0.65	$0.67	$13.1749 billion	$13.1680 billion	View	N/A
8/1/2017	Q2 2017	$0.65	$0.67	$13.0774 billion	$12.8960 billion	View	Listen
5/2/2017	Q1 2017	$0.67	$0.69	$13.0890 billion	$12.7790 billion	View	Listen
1/31/2017	Q416	$0.50	$0.47	$13.64 billion	$13.60 billion	View	N/A
11/1/2016	Q3	$0.62	$0.61	$13.05 billion	$13.05 billion	View	N/A
8/2/2016	Q216	$0.62	$0.64	$13.01 billion	$13.10 billion	View	N/A
5/3/2016	Q116	$0.55	$0.67	$12.00 billion	$13.00 billion	View	N/A
2/2/2016	Q415	$0.52	$0.53	$13.57 billion	$14.05 billion	View	N/A
10/27/2015	Q315	$0.51	$0.60	$11.56 billion	$12.10 billion	View	Listen
7/28/2015	Q215	$0.52	$0.56	$11.39 billion	$11.00 billion	View	Listen
4/28/2015	Q115	$0.49	$0.51	$10.79 billion	$10.86 billion	View	N/A
1/27/2015	Q414	$0.53	$0.54	$12.94 billion	$13.10 billion	View	N/A
10/28/2014	Q314	$0.55	$0.57	$12.24 billion	$12.40 billion	View	N/A
7/29/2014	Q214	$0.57	$0.58	$12.49 billion	$12.80 billion	View	N/A
5/5/2014	Q114	$0.56	$0.57	$12.07 billion	$11.35 million	View	N/A
1/27/2014	Q413	$0.52	$0.56	$13.35 billion	$13.56 billion	View	N/A
10/29/2013	Q313	$0.56	$0.58	$12.69 billion	$12.64 billion	View	N/A
7/30/2013	Q2 2013	$0.55	$0.56	$13.02 billion	$12.97 billion	View	Listen
4/30/2013	Q1 2013	$0.55	$0.54	$14.10 billion	$13.50 billion	View	Listen
1/29/2013	Q4 2012	$0.44	$0.47	$14.40 billion	$15.10 billion	View	Listen
11/1/2012	Q312	$0.53	$0.53	$14.64 billion	$14.00 billion	View	N/A
7/31/2012		$0.54	$0.62			View	N/A
5/1/2012		$0.57	$0.58			View	N/A
1/31/2012		$0.47	$0.50			View	N/A
11/1/2011		$0.55	$0.62			View	N/A
8/2/2011		$0.59	$0.60			View	N/A
5/3/2011		$0.59	$0.60			View	N/A
2/1/2011		$0.46	$0.47			View	N/A
11/2/2010	Q3 2010	$0.51	$0.54			View	N/A
8/3/2010	Q2 2010	$0.52	$0.62			View	N/A
5/4/2010	Q1 2010	$0.53	$0.60			View	N/A
2/3/2010	Q4 2009	$0.49	$0.49			View	N/A
10/20/2009	Q3 2009	$0.48	$0.51			View	N/A
7/22/2009	Q2 2009	$0.46	$0.48			View	N/A
4/28/2009	Q1 2009	$0.48	$0.54			View	N/A
1/26/2009	Q4 2008	$0.60	$0.65			View	N/A
10/21/2008	Q3 2008	$0.60	$0.62			View	N/A
7/23/2008	Q2 2008	$0.54	$0.55			View	N/A
4/17/2008	Q1 2008	$0.65	$0.61			View	N/A
1/23/2008	Q4 2007	$0.47	$0.52			View	N/A

(Earnings results data provided by Zacks Investment Research)

Pfizer (NYSE:PFE) Dividend Information

Pfizer pays an annual dividend of $1.36 per share, with a dividend yield of 3.71%. PFE's most recent quarterly dividend payment was Thursday, March 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 7.20% each year. Pfizer pays out 51.32% of its earnings out as a dividend.

Most Recent Dividend:	3/1/2018
Annual Dividend:	$1.36
Dividend Yield:	3.71%
Dividend Growth:	7.20% (3 Year Average)
Payout Ratio:	51.32% (Trailing 12 Months of Earnings) 45.95% (Based on This Year's Estimates) 44.59% (Based on Next Year's Estimates)
Track Record:	8 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
12/18/2017	quarterly	$0.34	3.68%	2/1/2018	2/2/2018	3/1/2018
9/27/2017	quarterly	$0.32	3.6%	11/9/2017	11/10/2017	12/1/2017
6/22/2017	quarterly	$0.32	3.75%	8/2/2017	8/4/2017	9/1/2017
4/28/2017	quarterly	$0.32	3.77%	5/10/2017	5/12/2017	6/1/2017
12/12/2016	quarterly	$0.32	3.9%	2/1/2017	2/3/2017	3/1/2017
9/23/2016	quarterly	$0.30	3.5%	11/8/2016	11/11/2016	12/1/2016
6/23/2016	quarterly	$0.30	3.53%	8/3/2016	8/5/2016	9/1/2016
4/28/2016	quarterly	$0.30	3.67%	5/11/2016	5/13/2016	6/1/2016
12/14/2015	quarterly	$0.30	3.72%	2/3/2016	2/5/2016	3/2/2016
9/25/2015	quarterly	$0.28	3.63%	11/4/2015	11/6/2015	12/1/2015
6/25/2015	quarterly	$0.28	3.3%	8/5/2015	8/7/2015	9/2/2015
4/23/2015	quarterly	$0.28	3.18%	5/6/2015	5/8/2015	6/2/2015
12/15/2014	quarterly	$0.28	3.65%	2/4/2015	2/6/2015	3/3/2015
10/23/2014	quarterly	$0.26	3.57%	11/5/2014	11/7/2014	12/2/2014
6/26/2014	quarterly	$0.26	3.51%	7/30/2014	8/1/2014	9/3/2014
4/25/2014	quarterly	$0.26	3.38%	5/7/2014	5/9/2014	6/3/2014
12/16/2013	quarterly	$0.26	3.45%	2/5/2014	2/7/2014	3/4/2014
10/24/2013	quarterly	$0.24	3.14%	11/6/2013	11/8/2013	12/3/2013
6/27/2013	quarterly	$0.24	3.43%	7/31/2013	8/2/2013	9/4/2013
4/25/2013	quarterly	$0.24	3.19%	5/8/2013	5/10/2013	6/4/2013
12/17/2012	quarterly	$0.24	3.74%	1/30/2013	2/1/2013	3/5/2013

(Data available from 1/1/2013 forward)

Pfizer (NYSE PFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 71.19%

Insider Trading History for Pfizer (NYSE:PFE)

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer (NYSE PFE) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2018	Douglas M Lankler	Insider	Sell	50,000	$36.89	$1,844,500.00	133,057
3/13/2018	Rady A Johnson	EVP	Sell	27,323	$36.55	$998,655.65	70,332
3/9/2018	Mikael Dolsten	Insider	Sell	69,699	$36.59	$2,550,286.41	120,784
3/6/2018	Charles H Hill	Insider	Sell	42,393	$35.76	$1,515,973.68
3/2/2018	Mikael Dolsten	Insider	Sell	13,986	$35.85	$501,398.10	120,884
2/27/2018	Sally Susman	EVP	Sell	33,368	$37.03	$1,235,617.04	191,505
2/27/2018	W Don Cornwell	Director	Sell	1,758	$36.79	$64,676.82	1,000
2/26/2018	Kirsten Lund-Jurgensen	Insider	Sell	9,510	$37.19	$353,676.90	36,959
12/15/2017	Alexander R Mackenzie	Insider	Sell	6,750	$37.00	$249,750.00	103,458
12/15/2017	Rady A Johnson	EVP	Sell	8,000	$37.07	$296,560.00	46,963
11/1/2017	Alexander R Mackenzie	Insider	Sell	14,700	$35.30	$518,910.00	117,432
10/2/2017	Alexander R Mackenzie	EVP	Sell	7,350	$35.65	$262,027.50	117,432
9/12/2017	Sally Susman	Insider	Sell	38,230	$35.00	$1,338,050.00	145,649
9/1/2017	Alexander R Mackenzie	Insider	Sell	7,350	$34.00	$249,900.00	124,774
8/31/2017	Alexander R Mackenzie	Insider	Sell	7,350	$34.00	$249,900.00	132,124
8/31/2017	Frank A Damelio	EVP	Sell	94,409	$34.00	$3,209,906.00	337,389
8/31/2017	Ian C Read	CEO	Sell	197,168	$34.00	$6,703,712.00	580,318
8/21/2017	Laurie J Olson	Insider	Sell	8,064	$32.70	$263,692.80	74,506
8/7/2017	Alexander R Mackenzie	Insider	Sell	15,000	$33.50	$502,500.00	151,474
8/4/2017	Ian C. Read	CEO	Sell	96,950	$34.00	$3,296,300.00
3/10/2017	Rady A Johnson	Insider	Sell	4,500	$34.19	$153,855.00	54,963
3/9/2017	Charles H Hill	Insider	Sell	36,000	$34.07	$1,226,520.00	57,329
3/2/2017	Mikael Dolsten	Insider	Sell	30,970	$34.51	$1,068,774.70	64,719
11/9/2016	Anthony J Maddaluna	Insider	Sell	10,000	$33.00	$330,000.00	112,087
11/4/2016	Albert Bourla	Insider	Sell	18,390	$30.05	$552,619.50	149,199
5/26/2016	Frank A Damelio	EVP	Sell	100,000	$34.49	$3,449,000.00	472,994
5/24/2016	Loretta V Cangialosi	VP	Sell	86,000	$33.97	$2,921,420.00	271,663
5/11/2016	Laurie J Olson	EVP	Sell	4,700	$33.50	$157,450.00	71,659
5/10/2016	Frank A Damelio	EVP	Sell	192,000	$33.66	$6,462,720.00	564,994
5/10/2016	John D Young	Insider	Sell	41,700	$33.53	$1,398,201.00	200,399
5/9/2016	Anthony J Maddaluna	EVP	Sell	8,950	$33.75	$302,062.50	88,922
5/9/2016	Ian C Read	CEO	Sell	275,000	$33.80	$9,295,000.00	1,446,738
5/5/2016	Sally Susman	EVP	Sell	76,116	$33.75	$2,568,915.00	195,951
5/4/2016	Douglas M Lankler	EVP	Sell	29,700	$33.69	$1,000,593.00	124,920
5/4/2016	Mikael Dolsten	Insider	Sell	67,588	$33.46	$2,261,494.48	438,107
5/3/2016	Frank A Damelio	EVP	Sell	87,079	$33.65	$2,930,208.35	372,994
10/6/2015	Pfizer Inc	major shareholder	Buy	714,285	$7.00	$4,999,995.00	2,489,364
6/11/2015	Laurie J Olson	EVP	Sell	26,000	$34.39	$894,140.00
3/12/2015	Sally Susman	EVP	Sell	46,179	$34.00	$1,570,086.00
2/13/2015	Loretta V Cangialosi	VP	Sell	104,000	$34.73	$3,611,920.00
2/12/2015	Anthony J Maddaluna	EVP	Sell	9,000	$34.85	$313,650.00
2/11/2015	Frank A Damelio	EVP	Sell	14,800	$34.30	$507,640.00
2/10/2015	Anthony J Maddaluna	EVP	Sell	9,000	$33.78	$304,020.00
12/8/2014	Anthony J Maddaluna	EVP	Sell	6,500	$32.00	$208,000.00
11/10/2014	Charles H Hill	EVP	Sell	8,285	$30.18	$250,041.30
11/7/2014	John D Young	Insider	Sell	21,600	$29.89	$645,624.00
10/29/2014	Anthony J Maddaluna	EVP	Sell	2,425	$29.56	$71,683.00
6/12/2014	Laurie J Olson	EVP	Sell	36,275	$29.53	$1,071,200.75
6/2/2014	Geno J Germano	Insider	Sell	30,000	$29.68	$890,400.00
3/17/2014	John Young	Insider	Sell	9,000	$31.38	$282,420.00	99,647
3/4/2014	Loretta Cangialosi	VP	Sell	102,943	$32.05	$3,299,323.15	171,756
3/4/2014	Mikael Dolsten	Insider	Sell	35,789	$32.58	$1,166,005.62	344,571
3/4/2014	Sally Susman	EVP	Sell	67,585	$32.59	$2,202,595.15	173,637
1/13/2014	Frank Damelio	EVP	Sell	131,810	$30.82	$4,062,384.20	356,451
11/1/2013	Anthony J Maddaluna	EVP	Sell	43,500	$31.02	$1,349,370.00
11/1/2013	Loretta V Cangialosi	VP	Sell	10,000	$31.20	$312,000.00
10/28/2013	Ian C Read	CEO	Sell	338,000	$30.57	$10,332,660.00
9/16/2013	Freda Lewis-Hall	EVP	Sell	38,461	$28.70	$1,103,830.70	118,383
7/31/2013	Charles H Hill	EVP	Sell	96,500	$29.64	$2,860,260.00
7/31/2013	Loretta V Cangialosi	VP	Sell	14,688	$29.63	$435,205.44
5/15/2013	Amy W Schulman	EVP	Sell	70,000	$29.36	$2,055,200.00
5/15/2013	Ian C Read	CEO	Sell	69,900	$29.39	$2,054,361.00

(Data available from 1/1/2013 forward)

Pfizer (NYSE PFE) News Headlines

Source:

Date	Headline
	See Which Of The Latest 13F Filers Holds Pfizer www.nasdaq.com - April 21 at 10:18 AM
	$13.03 Billion in Sales Expected for Pfizer (PFE) This Quarter www.americanbankingnews.com - April 21 at 1:56 AM
	Asembia Expands Collaboration with Pfizer Oncology www.prnewswire.com - April 20 at 10:55 AM
	Pfizer (PFE) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 20 at 3:28 AM
	Pfizer (PFE) Expected to Post Earnings of $0.73 Per Share www.americanbankingnews.com - April 19 at 11:14 PM
	FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC finance.yahoo.com - April 19 at 3:37 PM
	Pfizer Invites Public to Listen to Webcast of April 26 Annual Meeting of Shareholders finance.yahoo.com - April 19 at 3:37 PM
	Pfizer (PFE) Given a $43.00 Price Target by Cowen Analysts www.americanbankingnews.com - April 19 at 12:16 PM
	Pfizer (PFE) to Post FY2020 Earnings of $3.18 Per Share, SunTrust Banks Forecasts www.americanbankingnews.com - April 19 at 7:38 AM
	How Analysts View Tetraphase Pharmaceuticals in April 2018 finance.yahoo.com - April 18 at 3:37 PM
	BRIEF-IBT Urges Pfizer Shareholders To Vote For Proposal 7 For Corporate Political Spending Disclosure www.reuters.com - April 18 at 10:38 AM
	SunTrust Banks Weighs in on Pfizer's Q1 2018 Earnings (PFE) www.americanbankingnews.com - April 18 at 7:52 AM
	Coke Versus Pepsi of Drugmakers? Wall Street Doesn't Buy It finance.yahoo.com - April 17 at 3:43 PM
	Pfizer Inc. Stock Has a Great Storyline That's Not Panning Out finance.yahoo.com - April 17 at 10:44 AM
	J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance finance.yahoo.com - April 17 at 10:44 AM
	Biovica International - Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress www.prnewswire.com - April 17 at 3:42 AM
	Pfizer Inc. Stock Has a Great Storyline That’s Not Panning Out investorplace.com - April 17 at 12:03 AM
	Merck to move scientists and money toward promising cancer drug finance.yahoo.com - April 16 at 3:44 PM
	Pfizer Doesn't Succeed In One Late-Stage Kidney Cancer Study, What Else Is Left On The Table? seekingalpha.com - April 16 at 10:27 AM
	Pfizer (PFE) Short Interest Down 31.2% in March www.americanbankingnews.com - April 16 at 3:03 AM
	Q1 2018 Earnings Forecast for Pfizer (PFE) Issued By Jefferies Group www.americanbankingnews.com - April 16 at 1:17 AM
	Brainstorm Health: Gene Editing Arms Race, Pfizer Duchenne Drug, Concentrated Caffeine fortune.com - April 14 at 3:20 PM
	Berenberg Bank Analysts Give Pfizer (PFE) a $39.00 Price Target www.americanbankingnews.com - April 14 at 3:07 PM
	Pfizer (PFE) Rating Increased to Outperform at BMO Capital Markets www.americanbankingnews.com - April 14 at 10:35 AM
	Pfizer (PFE) Given a $35.00 Price Target at Jefferies Group www.americanbankingnews.com - April 14 at 10:05 AM
	Pfizer takes big gene therapy step after acquisition in Chapel Hill finance.yahoo.com - April 13 at 3:39 PM
	Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug finance.yahoo.com - April 13 at 3:39 PM
	Mylan Denies Report It's Interested In Buying Merck KGaA's Consumer Biz finance.yahoo.com - April 13 at 3:39 PM
	Tishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction Loan www.wsj.com - April 13 at 10:59 AM
	Mylan Reportedly Interested Merck KGaA's Consumer Health Unit finance.yahoo.com - April 13 at 10:59 AM
	Pfizer (PFE) Given a $38.00 Price Target by Jefferies Group Analysts www.americanbankingnews.com - April 13 at 9:39 AM
	Dow Jones Component Pfizer Isn't Interested In Bristol — Yet finance.yahoo.com - April 12 at 3:40 PM
	Pfizer (PFE) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - April 12 at 12:33 PM
	Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular ... www.businesswire.com - April 12 at 11:33 AM
	Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy finance.yahoo.com - April 12 at 11:33 AM
	Pfizer’s Inlyta Expansion Thwarted by Failed Phase III Study finance.yahoo.com - April 12 at 11:33 AM
	Olumiant Could Boost Incyte’s Revenues finance.yahoo.com - April 12 at 11:33 AM
	Pfizer Advances in Cancer Cell Therapy with Allogene Agreement finance.yahoo.com - April 12 at 11:33 AM
	Pfizer's (PFE) "Sell" Rating Reiterated at Citigroup www.americanbankingnews.com - April 12 at 11:07 AM
	UAB to receive funding from Pfizer for rheumatoid arthritis study finance.yahoo.com - April 11 at 3:38 PM
	Pfizer (PFE) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 11 at 1:48 PM
	Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell ... www.businesswire.com - April 11 at 11:16 AM
	Pfizer to Move Its Global Headquarters to Hudson Yards Tower www.bloomberg.com - April 11 at 11:16 AM
	Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III finance.yahoo.com - April 11 at 11:16 AM
	Pfizer (PFE) Given a $37.00 Price Target by Berenberg Bank Analysts www.americanbankingnews.com - April 11 at 8:58 AM
	Pfizer Joins the TriNetX Global Health Research Network Formed to Improve Clinical Trial Design and Accelerate the ... www.prnewswire.com - April 10 at 3:34 PM
	[$$] Tishman Speyer Inks Deal With Pfizer and Wins $1.8 Billion Construction Loan finance.yahoo.com - April 10 at 3:34 PM
	Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery finance.yahoo.com - April 10 at 3:34 PM
	Pfizer (PFE) Receives "Hold" Rating from Berenberg Bank www.americanbankingnews.com - April 10 at 1:11 PM
	Developer Tishman Speyer secures funds for $3.7 bln New York office tower finance.yahoo.com - April 10 at 10:56 AM

Pfizer (NYSE:PFE) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Pfizer (NYSE:PFE) Income Statement, Balance Sheet and Cash Flow Statement

Pfizer (NYSE PFE) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff